Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Honigman Represents Gemphire Therapeutics Inc. in $30 Million IPO

Honigman Miller Schwartz and Cohn LLP
Posted on: 31 Aug 16

Honigman Miller Schwartz and Cohn LLP advised Gemphire Therapeutics Inc. on its $30 million initial public offering. The company's common stock now trades on The NASDAQ Global Market under the symbol "GEMP."

Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. Canaccord Genuity acted as co-lead manager and Laidlaw & Company (UK) Ltd. and LifeSci Capital acted as co-managers.

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and nonalcoholic fatty liver disease.

The Honigman corporate and securities team advising Gemphire Therapeutics Inc. included Phillip D. Torrence, Meredith Ervine, Gabrielle Sims, Joscelyn Boucher, Cindy Bott and Stephanie Swan.

About Honigman Miller Schwartz and Cohn LLP

Honigman Miller Schwartz and Cohn LLP is a business law firm with nearly 300 attorneys serving clients locally, nationally and internationally. Headquartered in Detroit, the firm has offices in Ann Arbor, Bloomfield Hills, Kalamazoo and Lansing, Michigan and in Chicago, Illinois.

View source version on

Business Wire

Last updated on: 31/08/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.